Skip to main content

The FDA Asks Bayer To Submit Problems Linked With Essure

The FDA Asks Bayer To Submit Problems Linked With Essure

The FDA Asks Bayer To Submit Problems Linked With Essure

Introduction

Last week, the U.S. Food and Drug Administration (FDA) issued a letter to Bayer indicating requirements for submitting adverse event reports and postmarket activities associated with Essure, a permanent birth control device sold in the U.S. until 2018.

According to the letter issued, Bayer gets a variance, considering the anticipated volume and nature of the information, which gives the company a year to submit postmarket adverse event reports. The variance was requested by the manufacturer as it was receiving information about problems with the recalled Essure birth control device through social media and other adverse event reports.

The variance is valid for one year unless the FDA extends it, after which the manufacturer will be required to follow the regular adverse event reporting requirements for all Essure-associated reportable events.

The reports received by the manufacturer will be made publicly available by the FDA at pre-specified time points over the next year, starting in July 2020.

Nearly 18,000 lawsuits have been filed against Bayer, each involving similar allegations that the permanent birth control device resulted in painful and debilitating complications.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!